137 related articles for article (PubMed ID: 26875150)
1. Splenomegaly and thrombosis risk in essential thrombocythemia: the Mayo Clinic experience.
Haider M; Gangat N; Hanson C; Tefferi A
Am J Hematol; 2016 May; 91(5):E296-7. PubMed ID: 26875150
[No Abstract] [Full Text] [Related]
2. Uncontrolled thrombocytosis in polycythemia vera is a risk for thrombosis, regardless of JAK2(V617F) mutational status.
Ohyashiki K; Akahane D; Gotoh A; Ito Y; Tauchi T; Miyazawa K; Kimura Y; Ohyashiki JH
Leukemia; 2007 Dec; 21(12):2544-5. PubMed ID: 17611562
[No Abstract] [Full Text] [Related]
3. Comparison between thrombotic risk scores in essential thrombocythemia and survival implications.
Santoro M; Accurso V; Mancuso S; Carlisi M; Raso S; Tarantino G; Di Piazza F; Perez A; Russo A; Siragusa S
Hematol Oncol; 2019 Oct; 37(4):434-437. PubMed ID: 31465530
[TBL] [Abstract][Full Text] [Related]
4. Extreme thrombocytosis in low-risk essential thrombocythemia: Retrospective review of vascular events and treatment strategies.
Tefferi A; Szuber N; Pardanani A; Hanson CA; Vannucchi AM; Barbui T; Gangat N
Am J Hematol; 2021 Jun; 96(6):E182-E184. PubMed ID: 33617676
[No Abstract] [Full Text] [Related]
5. Spleen enlargement is a risk factor for thrombosis in essential thrombocythemia: Evaluation on 1,297 patients.
Andriani A; Latagliata R; Anaclerico B; Spadea A; Rago A; Di Veroli A; Spirito F; Porrini R; De Muro M; Crescenzi Leonetti S; Villivà N; De Gregoris C; Montefusco E; Polverelli N; Santoro C; Breccia M; Cimino G; Majolino I; Mazzucconi MG; Vianelli N; Alimena G; Montanaro M; Palandri F
Am J Hematol; 2016 Mar; 91(3):318-21. PubMed ID: 26748894
[TBL] [Abstract][Full Text] [Related]
6. Validation of previous prognostic models for thrombosis and exploration of modified models in patients with essential thrombocythemia.
Hashimoto Y; Nakamae H; Tanaka T; Omura H; Horiuchi M; Yoshimura T; Takakuwa T; Mugitani A; Hirose A; Nakamae M; Koh H; Hino M
Eur J Haematol; 2018 Oct; 101(4):508-513. PubMed ID: 29971894
[TBL] [Abstract][Full Text] [Related]
7. Platelet turnover, coagulation factors, and soluble markers of platelet and endothelial activation in essential thrombocythemia: relationship with thrombosis occurrence and JAK2 V617F allele burden.
Arellano-Rodrigo E; Alvarez-Larrán A; Reverter JC; Colomer D; Villamor N; Bellosillo B; Cervantes F
Am J Hematol; 2009 Feb; 84(2):102-8. PubMed ID: 19105233
[TBL] [Abstract][Full Text] [Related]
8. JAK2 exon 12 mutated polycythemia vera: Mayo-Careggi MPN Alliance study of 33 consecutive cases and comparison with JAK2V617F mutated disease.
Tefferi A; Lavu S; Mudireddy M; Lasho TL; Finke CM; Gangat N; Pardanani A; Hanson CA; Mannarelli C; Guglielmelli P; Vannucchi AM
Am J Hematol; 2018 Aug; 93(4):E93-E96. PubMed ID: 29274140
[No Abstract] [Full Text] [Related]
9. Mutations and thrombosis in essential thrombocythemia: prognostic interaction with age and thrombosis history.
Gangat N; Wassie EA; Lasho TL; Finke C; Ketterling RP; Hanson CA; Pardanani A; Wolanskyj AP; Maffioli M; Casalone R; Passamonti F; Tefferi A
Eur J Haematol; 2015 Jan; 94(1):31-6. PubMed ID: 24889737
[TBL] [Abstract][Full Text] [Related]
10. Prognostic utility of spontaneous erythroid colony formation and JAK2 mutational analysis for thrombotic events in essential thrombocythaemia.
Weston H; Cowell V; Grimmett K; Saal R; Jones M; Mills T; Gill D; Marlton P; Bird R; Mollee P
Intern Med J; 2011 May; 41(5):408-15. PubMed ID: 20681956
[TBL] [Abstract][Full Text] [Related]
11. [Thrombotic events and significance of the IPSET thrombosis risk evaluation score in essential thrombocythaemia].
Pósfai É; Marton I; Nemes A; Borbényi Z
Orv Hetil; 2015 Apr; 156(14):558-63. PubMed ID: 25819149
[TBL] [Abstract][Full Text] [Related]
12. [Treatment of essential thrombocythemia].
Alvarez-Larrán A; Cervantes F; Besses C
Med Clin (Barc); 2013 Sep; 141(6):260-4. PubMed ID: 23490491
[TBL] [Abstract][Full Text] [Related]
13. Pregnancy complications predict thrombotic events in young women with essential thrombocythemia.
Randi ML; Bertozzi I; Rumi E; Elena C; Finazzi G; Vianelli N; Polverelli N; Ruggeri M; Vannucchi AM; Antonioli E; Lussana F; Tieghi A; Iurlo A; Elli E; Ruella M; Fabris F; Cazzola M; Barbui T
Am J Hematol; 2014 Mar; 89(3):306-9. PubMed ID: 24265194
[TBL] [Abstract][Full Text] [Related]
14. Impact of JAK2V617F mutation on thrombosis and myeloid transformation in essential thrombocythemia: a multivariate analysis by Cox regression in 141 patients.
Chim CS; Sim JP; Chan CC; Kho BC; Chan JC; Wong LG; Law M; Liang R; Kwong YL
Hematology; 2010 Aug; 15(4):187-92. PubMed ID: 20670476
[TBL] [Abstract][Full Text] [Related]
15. The relationship between factor V Leiden, prothrombin G20210A, and MTHFR mutations and the first major thrombotic episode in polycythemia vera and essential thrombocythemia.
Trifa AP; Cucuianu A; Popp RA; Coadă CA; Costache RM; Militaru MS; Vesa ŞC; Pop IV
Ann Hematol; 2014 Feb; 93(2):203-9. PubMed ID: 23828072
[TBL] [Abstract][Full Text] [Related]
16. Calreticulin mutation does not modify the IPSET score for predicting the risk of thrombosis among 1150 patients with essential thrombocythemia.
Finazzi G; Carobbio A; Guglielmelli P; Cavalloni C; Salmoiraghi S; Vannucchi AM; Cazzola M; Passamonti F; Rambaldi A; Barbui T
Blood; 2014 Oct; 124(16):2611-2. PubMed ID: 25323688
[No Abstract] [Full Text] [Related]
17. JAK2 V617F-positive latent essential thrombocythemia and splanchnic vein thrombosis: the role of bone marrow biopsy for the diagnosis of myeloproliferative disease.
Allegra A; Alonci A; Penna G; D'Angelo A; Rizzotti P; Granata A; Musolino C
Acta Haematol; 2009; 121(4):218-20. PubMed ID: 19478480
[TBL] [Abstract][Full Text] [Related]
18. Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia.
Barbui T; Vannucchi AM; Buxhofer-Ausch V; De Stefano V; Betti S; Rambaldi A; Rumi E; Ruggeri M; Rodeghiero F; Randi ML; Bertozzi I; Gisslinger H; Finazzi G; Carobbio A; Thiele J; Passamonti F; Falcone C; Tefferi A
Blood Cancer J; 2015 Nov; 5(11):e369. PubMed ID: 26617062
[No Abstract] [Full Text] [Related]
19. Increased risk of recurrent thrombosis in patients with essential thrombocythemia carrying the homozygous JAK2 V617F mutation.
De Stefano V; Za T; Rossi E; Vannucchi AM; Ruggeri M; Elli E; Micò C; Tieghi A; Cacciola RR; Santoro C; Vianelli N; Guglielmelli P; Pieri L; Scognamiglio F; Cacciola E; Rodeghiero F; Pogliani EM; Finazzi G; Gugliotta L; Leone G; Barbui T;
Ann Hematol; 2010 Feb; 89(2):141-6. PubMed ID: 19582452
[TBL] [Abstract][Full Text] [Related]
20. Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients.
Passamonti F; Rumi E; Arcaini L; Boveri E; Elena C; Pietra D; Boggi S; Astori C; Bernasconi P; Varettoni M; Brusamolino E; Pascutto C; Lazzarino M
Haematologica; 2008 Nov; 93(11):1645-51. PubMed ID: 18790799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
